Inve US ▾

Travere Therapeutics (TVTX) earnings

Travere Therapeutics, Inc.· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025
Build an Inve Case for TVTX

Company research is public. Sign in to keep your own companies, notes and cases.

Travere Therapeutics earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue170 $ million+48.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin2.3 %+13.4 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-34.8 $ million—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

9 of 9 judged targets kept · 8 open · verdicts reflect calls analysed to Jun 2026.

TargetOriginal wordingSaidLatest callVerdict
Data readout from post-transplant recurrent FSGS/IgAN studyAnticipate data from this study in 2027Jun 2026Jun 2026:We recently completed enrollment in our post-transplant study evaluating recurrent FSGS and recurrent IgA nephropathy, areas of significant unmet need. We anticipate data from this study in 2027.
Call transcript, Jun 2026 · no direct link		New
FDA full approval of FILSPARI (sparsentan) in FSGSPotential full FDA approval for sparsentan in FSGS in 2025 (year-end 2025), contingent on sNDA submissionSep 2024Mar 2026:We achieved the first FDA approval in FSGS
Call transcript, Mar 2026 · no direct link		Achieved*

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

8 of Travere Therapeutics, Inc.'s 17 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 15 more targets are in the full ledger.

Create a free account Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$52.79 −0.90% · −$0.48

Last close Oct 15, 2026 · US · USD

Performance +102.0% 1Y

$30.0$40.0$50.0$60.0$70.0Oct 25Nov 25Jan 26Feb 26Apr 26May 26Jul 26Aug 26Oct 26Mar 2026 (Q1 FY26) — 4 May 2026Jun 2026 (Q2 FY26) — 4 Aug 2026

1Y: $26.14 on 14 Oct 2025 → $52.79. High $67.52 (27 Aug 2026), low $26.14 (14 Oct 2025).

Previous close
$53.27
52-week range
$26.14 – $67.52
One year
+96.61%

Overview

Symbol
TVTX
Exchange
US
Currency
USD

Your own record

Start an Inve Case for Travere Therapeutics, Inc.

Free account. Everything above stays public.

Write why you follow Travere Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

Create your Inve Case What an account adds

Keep reading

Other US companies filed under T

All 170 companies under T

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered